Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

apitolisib (GDC-0980)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

mTOR inhibitor, PI3K inhibitor

Related drugs:

‹

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

albumin-bound (0)

enzastaurin (3)

BAY 1082439 (1)

›

PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck	GDC-0980 Sensitive: C3 – Early Trials GDC-0980 Sensitive : C3	GDC-0980 Sensitive: C3 – Early Trials GDC-0980 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	GDC-0980 Sensitive: D – Preclinical GDC-0980 Sensitive : D	GDC-0980 Sensitive: D – Preclinical GDC-0980 Sensitive : D
STK11 expression	Non Small Cell Lung Cancer	STK11 expression	Non Small Cell Lung Cancer	GDC-0980 Sensitive: D – Preclinical GDC-0980 Sensitive : D	GDC-0980 Sensitive: D – Preclinical GDC-0980 Sensitive : D
PTEN expression	Breast Cancer	PTEN expression	Breast Cancer	GDC-0980 Sensitive: D – Preclinical GDC-0980 Sensitive : D	GDC-0980 Sensitive: D – Preclinical GDC-0980 Sensitive : D